This statement in todays announcement is the part that shouts out to me
“Not only does this enable us to progress to a multiple dose study in RP11 with high conviction but it also has important read-through implications for the remainder of our ocular pipeline as this is the first time the RNA conjugate modality has ever been used in a human eye.”
My thoughts are that the implications of this to all other bio tech companies working in the field of monogenic eye diseases would have to have them and the likes of Roche (who bought Spark Therapeutics) paying serious attention to PYC from both a medical discover perspective and a financial investment point of view.
I am getting excited about the future
PYC Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)